Urology · BPHRegulatory Approvalregulatorymid-term

Aurobindo Pharma submits SUPPL for Alfuzosin Hydrochloride (ANDA079060)

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:05:09 AM

Assessment confidence: 67% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The submission of a supplemental application for Alfuzosin Hydrochloride by Aurobindo Pharma could alter the competitive dynamics in the BPH treatment market. Portfolio teams need to evaluate the implications for market entry and positioning against existing therapies. Regulatory context from FDA (FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry timing and competitive positioning against existing therapies. The strongest clinical anchor is Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Urology · BPH, 8 regulatory and 4 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo). This submission may impact the competitive landscape for BPH treatments, particularly among generic alternatives.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The approval process for the supplemental application could influence compliance and labeling requirements for existing products in the market.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a new generic alternative may affect market share and pricing strategies for current BPH treatments, potentially impacting revenue streams.
Upside for Aurobindo Pharma may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Upside for Aurobindo Pharma may improve if Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function (ClinicalTrials.gov) delivers favorable follow-through.
Rare Diseases · Various · Regulatory Approval · This initiative could enhance the speed of market access for new therapies, potentially benefiting companies developing treatments for rare diseases in the UK.
Portfolio teams should assess the potential market entry timing and competitive positioning against existing therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the review status and any subsequent approvals or market entries related to this application.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MEPERIDINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pomegranate Dietary Supplements in AUD and ALD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea:
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment
MHRA Launches Consultation for Earlier Licensing of Rare Disease Therapies
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Systemic challenges in the supply and distribution of medicines in conflict-affected areas of Mali: a qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Alfuzosin Hydrochloride

Commercial impact

medium

The introduction of a new generic alternative may affect market share and pricing strategies for current BPH treatments, potentially impacting revenue streams.

Regulatory impact

medium

The approval process for the supplemental application could influence compliance and labeling requirements for existing products in the market.

What to watch

Monitor the review status and any subsequent approvals or market entries related to this application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.